Project no.: HIV-NAT 200/GS-US-292-0117
This study is divided into 2 parts.
Part 1 is a randomized, double-blind comparison of the addition of tenofovir alafenamide (TAF) or placebo to the antiviral (ARV) regimens of HIV-positive adults who are failing their current ARV regimen.
In Part 2, after a 14-day washout period all participants will receive open-label elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimen (E/C/F/TAF STR) and be followed for at least 48 weeks.